Cameron Scott J, Gerhardt Gregory, Engelstad Michael, Young Mark A, Norris Edward J, Sokoll Lori J
Department of Pathology, Clinical Chemistry Division, Johns Hopkins Medical Institutions, Meyer B-125 600 N. Wolfe Street, Baltimore, MD 21287, USA.
Clin Biochem. 2009 Feb;42(3):221-4. doi: 10.1016/j.clinbiochem.2008.10.023. Epub 2008 Nov 11.
To evaluate interference by the hemoglobin-based oxygen carrier Hemospan on clinical laboratory assays.
Interfering Hemospan concentrations were determined for general chemistry and cardiac marker analytes in pooled serum and the corresponding hemolysis index was calculated.
Hemospan did not interfere with 20 of 35 analytes. Hemospan produced a negative interference in serum creatinine, amylase, alkaline phosphatase, uric acid, and GGT assays and a positive interference in serum phosphate, LDH, iron, triglycerides, total protein, AST, cholesterol, magnesium, and albumin assays, and appeared to positively bias the serum cardiac troponin I (cTnI) assay only when cTnI is present in the sample.
We present a report of assays affected by Hemospan and the threshold concentrations for interference. This study highlights the importance of interference studies in understanding the effects of hemoglobin-based oxygen carriers on results reported by the clinical laboratory.
评估基于血红蛋白的氧载体Hemospan对临床实验室检测的干扰。
测定混合血清中一般化学和心脏标志物分析物的Hemospan干扰浓度，并计算相应的溶血指数。
Hemospan对35种分析物中的20种无干扰。Hemospan对血清肌酐、淀粉酶、碱性磷酸酶、尿酸和γ-谷氨酰转移酶检测产生负干扰，对血清磷酸盐、乳酸脱氢酶、铁、甘油三酯、总蛋白、天门冬氨酸氨基转移酶、胆固醇、镁和白蛋白检测产生正干扰，并且仅当样本中存在心肌肌钙蛋白I（cTnI）时，似乎会使血清cTnI检测结果出现正偏差。
我们报告了受Hemospan影响的检测方法及干扰阈值浓度。本研究强调了干扰研究对于理解基于血红蛋白的氧载体对临床实验室报告结果的影响的重要性。
